Cell Transfection

Global Cell Transfection Market to Reach US$2.1 Billion by 2030

The global market for Cell Transfection estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Electroporation Method, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$773.1 Million by the end of the analysis period. Growth in the Lipofection Method segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$379.2 Million While China is Forecast to Grow at 10.7% CAGR

The Cell Transfection market in the U.S. is estimated at US$379.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$429.1 Million by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Cell Transfection Market – Key Trends & Drivers Summarized

Why Is Cell Transfection Gaining Ground in Modern Biomedical Research?

Cell transfection has evolved into a cornerstone technique in molecular biology and genetic engineering, driving progress across a spectrum of biomedical research and therapeutic development. This method enables the intentional introduction of foreign nucleic acids—such as DNA, RNA, or CRISPR-Cas9 components—into eukaryotic cells, facilitating gene expression, silencing, or editing. Its rising prominence is closely tied to the explosive growth in genomic research, functional genomics, and cell-based assays used in drug discovery and disease modeling. Academic labs, biotech startups, and pharmaceutical giants alike depend on transfection to validate gene targets, engineer therapeutic proteins, and optimize viral vector production.

The expanding scope of personalized medicine and cell therapies has intensified interest in advanced transfection technologies. Researchers are now leveraging transfection to modify immune cells (like T cells or NK cells) for cancer immunotherapy, manufacture recombinant biologics, and create gene-edited disease models. As interest in complex and chronic diseases such as cancer, neurodegeneration, and rare genetic disorders surges, the transfection market is seeing a parallel upswing in demand. The versatility of this tool is driving its integration into workflows across preclinical research, therapeutic development, and diagnostic innovation.

How Are Delivery Methods Evolving to Improve Efficiency and Safety?

Technological advances in transfection methodologies are addressing long-standing challenges related to delivery efficiency, cell viability, and scalability. Traditional techniques like chemical-based transfection (e.g., calcium phosphate or lipid reagents) and physical methods (like electroporation or microinjection) are being refined to improve uptake while minimizing cytotoxicity. New-generation lipid nanoparticles, polymeric carriers, and non-viral vectors offer enhanced biocompatibility and transfection efficiency, particularly for sensitive cell types such as primary neurons or stem cells.

Meanwhile, electroporation technology has made considerable strides, now offering programmable, automated systems that precisely control voltage and pulse duration for reproducible results. These are especially useful in large-scale clinical applications like CAR-T cell manufacturing. Researchers are also exploring hybrid systems that combine physical and chemical techniques for synergistic effects. The shift toward non-viral transfection systems is particularly notable, driven by safety concerns, ease of use, and regulatory advantages. These evolving modalities are expanding the range of target cells, improving reproducibility, and accelerating research timelines—key benefits fueling broader market adoption.

Why Are Biopharma and Academic Partnerships Accelerating Adoption?

A growing network of collaborations between academic institutions and biopharma companies is catalyzing innovation and scaling in the transfection landscape. Pharmaceutical companies are increasingly investing in transfection-based platforms to fast-track biologic and gene therapy pipelines. At the same time, universities and research hospitals are employing high-throughput transfection technologies to study gene function and disease pathways in real time. These partnerships often lead to joint ventures or licensing deals that expand market access and accelerate product development.

Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are also entering the fray, offering turnkey transfection services to clients lacking in-house expertise. This outsourcing trend is enabling smaller firms to participate in cutting-edge research without building extensive infrastructure. As regulatory pathways for cell and gene therapies become more defined, the need for consistent, scalable transfection methods is becoming critical. These ecosystem synergies between academia, industry, and service providers are streamlining workflows and widening the adoption of transfection technologies in both research and clinical settings.

What’s Powering the Unrelenting Growth of the Market?

The growth in the cell transfection market is driven by several factors. The surge in genetic research and the rise of precision medicine are compelling widespread use of transfection in preclinical and translational studies. Biopharma’s increasing reliance on transfection for gene therapy, monoclonal antibody production, and vaccine development is fueling demand for efficient, scalable, and safe delivery systems. Additionally, innovations in non-viral vectors, automation, and high-throughput formats are expanding the technology’s applicability to a broader range of cell types and experimental designs. The expanding pipeline of gene-edited and cell-based therapies—particularly in oncology and rare disease treatment—is intensifying the need for GMP-compliant, clinical-grade transfection platforms. Also, the growth of academic and CRO/CDMO partnerships is facilitating knowledge transfer, reducing development costs, and enhancing access to transfection technologies across geographies. These cumulative forces are driving strong and sustained growth in the global cell transfection market.

SCOPE OF STUDY:

The report analyzes the Cell Transfection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Method (Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method, Other Methods); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Agilent Technologies Inc.
• Altogen Biosystems
• Applied Biological Materials Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Boca Scientific Inc.
• Dundee Cell Products Ltd
• Horizon Discovery Group plc
• Lonza Group Ltd
• MaxCyte Inc.
• Merck KGaA
• Mirus Bio LLC
• Molecular Devices
• OriGene Technologies, Inc.
• PerkinElmer Inc.
• Polyplus-transfection SA
• Promega Corporation
• QIAGEN N.V.
• Sartorius AG
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.